Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Net Cash Flow (2017 - 2025)

Sutro Biopharma's Net Cash Flow history spans 9 years, with the latest figure at $1.9 million for Q3 2025.

  • For Q3 2025, Net Cash Flow fell 97.73% year-over-year to $1.9 million; the TTM value through Sep 2025 reached -$108.7 million, down 217.17%, while the annual FY2024 figure was $121.0 million, 449.75% up from the prior year.
  • Net Cash Flow for Q3 2025 was $1.9 million at Sutro Biopharma, up from -$42.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $172.6 million in Q2 2023 and bottomed at -$153.3 million in Q3 2023.
  • The 5-year median for Net Cash Flow is -$293000.0 (2021), against an average of -$7.4 million.
  • The largest annual shift saw Net Cash Flow plummeted 21127.27% in 2021 before it skyrocketed 8648.08% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$293000.0 in 2021, then crashed by 16802.73% to -$49.5 million in 2022, then surged by 74.63% to -$12.6 million in 2023, then skyrocketed by 225.15% to $15.7 million in 2024, then plummeted by 87.91% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Net Cash Flow are $1.9 million (Q3 2025), -$42.2 million (Q2 2025), and -$84.1 million (Q1 2025).